Development and clinical evaluation of a multi-purpose mAb and a sandwich ELISA test for hepatoma-derived growth factor in lung cancer patients

Journal of Immunological Methods

Volumn 355, Issue 1-2, 2010, Pages 61-67

  Zhang, Aixia ^a   Long, Weiguo ^a   Guo, Ze ^a   Liu, Genyan ^b   Hu, Zhibin ^a   Huang, Yan ^a   Li, Yunqian ^a   Grabinski, Tessa M ^c   Yang, Jun ^d   Zhao, Ping X ^c   Everett, Allen D ^d   Zhang, Yan ^e   Cao, Brian B ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Hepatoma derived growth factor; Immunohistochemistry; MAb; NSCLC; Sandwich ELISA

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F12; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DENATURATION; SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEP G2 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MICE; NIH 3T3 CELLS; RABBITS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY;

ORYCTOLAGUS CUNICULUS;

EID: 77951204907     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.02.011     Document Type: Article

References (20)

1. Bernard K., Litman E., Fitzpatrick J.L., Shellman Y.G., Argast G., Polvinen K., Everett A.D., Fukasawa K., Norris D.A., Ahn N.G., Resing K.A. Functional proteomic analysis of melanoma progression. Cancer Res. 2003, 63(20):6716.
2. Dunant A., Pignon J.P., Le Chevalier T. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. Clin. Cancer Res. 2005, 11(13 Pt 2):5017s.
3. Enomoto H., Yoshida K., Kishima Y., Kinoshita T., Yamamoto M., Everett A.D., Miyajima A., Nakamura H. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002, 36(6):1519.
4. Everett A.D., Lobe D.R., Matsumura M.E., Nakamura H., McNamara C.A. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J. Clin. Invest. 2000, 105(5):567.
5. Everett A.D., Stoops T., McNamara C.A. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J. Biol. Chem. 2001, 276(40):37564.
6. Hu T.H., Lin J.W., Chen H.H., Liu L.F., Chuah S.K., Tai M.H. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis. Colon Rectum 2009, 52(2):319.
7. Iwasaki T., Nakagawa K., Nakamura H., Takada Y., Matsui K., Kawahara K. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol. Rep. 2005, 13(6):1075.
8. Kishima Y., Yamamoto H., Izumoto Y., Yoshida K., Enomoto H., Yamamoto M., Kuroda T., Ito H., Yoshizaki K., Nakamura H. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J. Biol. Chem. 2002, 277(12):10315.
9. Klagsbrun M., Sasse J., Sullivan R., Smith J.A. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc. Natl. Acad. Sci. U.S.A. 1986, 83(8):2448.
10. Lepourcelet M., Tou L., Cai L., Sawada J., Lazar A.J., Glickman J.N., Williamson J.A., Everett A.D., Redston M., Fox E.A., Nakatani Y., Shivdasani R.A. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development 2005, 132(2):415.
11. Okuda Y., Nakamura H., Yoshida K., Enomoto H., Uyama H., Hirotani T., Funamoto M., Ito H., Everett A.D., Hada T., Kawase I. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 2003, 94(12):1034.
12. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J. Clin. 1999, 49:33.
13. Ren H., Tang X., Lee J.J., Feng L., Everett A.D., Hong W.K., Khuri F.R., Mao L. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J. Clin. Oncol. 2004, 22(16):3230.
14. Uyama H., Tomita Y., Nakamura H., Nakamori S., Zhang B., Hoshida Y., Enomoto H., Okuda Y., Sakon M., Aozasa K., Kawase I., Hayashi N., Monden M. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin. Cancer Res. 2006, 12(20 Pt 1):6043.
15. Yamamoto S., Tomita Y., Hoshida Y., Takiguchi S., Fujiwara Y., Yasuda T., Doki Y., Yoshida K., Aozasa K., Nakamura H., Monden M. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin. Cancer Res. 2006, 12(1):117.
16. Yamamoto S., Tomita Y., Hoshida Y., Morii E., Yasuda T., Doki Y., Aozasa K., Uyama H., Nakamura H., Monden M. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann. Surg. Oncol. 2007, 14(7):2141.
17. Yang J., Everett A.D. Hepatoma-derived growth factor binds DNA through the N-terminal PWWP domain. BMC Mol. Biol. 2007, 8:101.
18. Yoshida K., Nakamura H., Okuda Y., Enomoto H., Kishima Y., Uyama H., Ito H., Hirasawa T., Inagaki S., Kawase I. Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J. Gastroenterol. Hepatol. 2003, 18(11):1293.
19. Yoshida K., Tomita Y., Okuda Y., Yamamoto S., Enomoto H., Uyama H., Ito H., Hoshida Y., Aozasa K., Nagano H., Sakon M., Kawase I., Monden M., Nakamura H. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann. Surg. Oncol. 2006, 13(2):159.
20. Zhang J., Ren H., Yuan P., Lang W., Zhang L., Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res. 2006, 66(1):18.